Bristol-Myers Squibb: Thromboembolism trials

The registry lists 12 Thromboembolism studies with Bristol-Myers Squibb as lead sponsor. 0 are open to participants now and 2 have results posted.

Phase 1 3Phase 2 1Phase 4 1No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Apixaban for the Acute Treatment of Venous Thromboembolism in ChildrenCompletedNCT02464969Phase 4Results posted
• A Phase 2 Pilot Study of Apixaban for the Prevention of Thromboembolic Events in Patients With Advanced (Metastatic) CancerCompletedNCT00320255Phase 2Results posted
• A Study of Hospital Healthcare Use and Cost in Patients in the Hospital With a Venous Thromboembolism (VTE) Treated With Apixaban or Warfarin in the USCompletedNCT04141228
• The Study of How Long Participants Stay in the Hospital After Receiving Apixaban for a Blood Clot in the LungCompletedNCT03595891
• A Study to Compare the Risk of a Major Bleeding in Participants Who Received Blood Thinning Medications Following a Blood ClotCompletedNCT03521908
• Treatment of Venous Thromboembolism in Real-Life PatientsCompletedNCT03087474
• Effect of Clarithromycin on the Pharmacokinetics of Apixaban in Healthy ParticipantsCompletedNCT02912234Phase 1
• ELIQUIS (APIXABAN) Regulatory Post-Marketing Surveillance In Clinical Practice for Venous Thromboembolism (VTE) Treatment and Prevention Of Recurrent VTECompletedNCT02836457
• Description of Patients With Acute Venous Thromboembolism in the UK's Clinical Practice Research Datalink Linked With Hospital Episode Statistics Dataset (CPRD-HES)CompletedNCT02661568
• Eliquis (VTE Treatment and Prevention of Recurrent VTE) rPMSCompletedNCT02546817
• Study to Evaluate a Single Dose of Apixaban in Pediatric Participants at Risk for a Thrombotic DisorderCompletedNCT01707394Phase 1
• Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous CatheterTerminatedNCT01195727Phase 1